179 related articles for article (PubMed ID: 15963495)
1. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets.
Asplund Persson A; Zalavary S; Lindström E; Whiss PA; Bengtsson T; Grenegård M
Eur J Pharmacol; 2005 Jul; 517(3):149-57. PubMed ID: 15963495
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
3. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine.
Grenegård M; Gustafsson MC; Andersson RG; Bengtsson T
Br J Pharmacol; 1996 Aug; 118(8):2140-4. PubMed ID: 8864553
[TBL] [Abstract][Full Text] [Related]
5. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L-penicillamine.
Asplund Persson AK; Palmér L; Gunnarsson P; Grenegård M
Eur J Pharmacol; 2004 Aug; 496(1-3):1-9. PubMed ID: 15288569
[TBL] [Abstract][Full Text] [Related]
7. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
9. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.
Kageyama K; Mizobe T; Nozuchi S; Hiramatsu N; Nakajima Y; Aoki H
J Anesth; 2004; 18(2):107-12. PubMed ID: 15127258
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide.
Martinez A; Salas E; Radomski A; Radomski MW
Med Sci Monit; 2001; 7(4):646-51. PubMed ID: 11433190
[TBL] [Abstract][Full Text] [Related]
11. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
12. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase.
Paul S; Feoktistov I; Hollister AS; Robertson D; Biaggioni I
Mol Pharmacol; 1990 Jun; 37(6):870-5. PubMed ID: 2359405
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
Sogo N; Magid KS; Shaw CA; Webb DJ; Megson IL
Biochem Biophys Res Commun; 2000 Dec; 279(2):412-9. PubMed ID: 11118301
[TBL] [Abstract][Full Text] [Related]
14. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels.
Lindgren SH; Andersson TL; Vinge E; Andersson KE
Acta Physiol Scand; 1990 Oct; 140(2):209-19. PubMed ID: 2176433
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems.
Corell T; Pedersen SB; Lissau B; Moilanen E; Metsä-Ketelä T; Kankaanranta H; Vuorinen P; Vapaatalo H; Rydell E; Andersson R
Pol J Pharmacol; 1994; 46(6):553-66. PubMed ID: 7542520
[TBL] [Abstract][Full Text] [Related]
16. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets.
Bani D; Bigazzi M; Masini E; Bani G; Sacchi TB
Lab Invest; 1995 Nov; 73(5):709-16. PubMed ID: 7474945
[TBL] [Abstract][Full Text] [Related]
17. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
18. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet adhesion to collagen by cGMP-elevating agents.
Wu CC; Ko FN; Teng CM
Biochem Biophys Res Commun; 1997 Feb; 231(2):412-6. PubMed ID: 9070290
[TBL] [Abstract][Full Text] [Related]
20. Benzodifuroxan as an NO-dependent activator of soluble guanylate cyclase and a novel highly effective inhibitor of platelet aggregation.
Bussygina OG; Pyatakova NV; Khropov YV; Ovchinnikov IV; Makhova NN; Severina IS
Biochemistry (Mosc); 2000 Apr; 65(4):457-62. PubMed ID: 10810184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
